Sooma Medical

Sooma operates at the intersection of medical devices, digital therapeutics, and non-invasive neuromodulation. Its offering combines a portable brain-stimulation device with prescription-based treatment protocols and remote clinical oversight, rather than positioning tDCS as a consumer wellness product. The company targets major depressive disorder, fibromyalgia, and chronic neuropathic pain, giving it a broader clinical application set than a depression-only therapy provider. Its stated differentiators include being the first and only MDR-approved tDCS treatment system to date, Finnish manufacturing under ISO 13485 quality standards, and deployment through more than 300 clinics, hospitals, and universities. Sooma also reports availability in more than 35 countries, suggesting an international clinical footprint despite a small disclosed employee base of one to ten people. The €5 million 2024 seed round places Sooma in an expansion phase, with capital likely supporting regulatory, clinical, and commercial scaling rather than broad platform diversification.

Sooma’s trajectory shows a progression from early-stage medical-device development toward regulated, distributed treatment delivery. The company was founded in 2013, followed by seed financing in June 2013 and December 2014. It then recorded a €345,000 venture round in March 2018 and a €1.2 million venture round in December 2019, with Kustaa Piha identified as lead investor. The largest disclosed inflection point came on Mar 12, 2024, when Sooma raised €5 million from Voima Ventures. That round increased the company’s reported cumulative funding to approximately $8.44 million and coincided with efforts to expand access to home-based depression treatment. Product development also advanced from the core Sooma tDCS™ system to Sooma Duo, launched in October 2023 with remote supervision, preset electrode placement, and automatic resistance control. Sooma Portal adds a digital layer for monitoring and treatment management. The company reports use in over 35 countries and collaboration with more than 300 institutions, but public hiring data is sparse and the disclosed team size remains one to ten employees. This indicates international product reach with limited visibility into operational scale.